Gene

FGFR2

fibroblast growth factor receptor 2

Explore in graph →CI-GENE-00001925HGNC:3689 ENSG00000066468 NCBI 2263 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (69)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 51–69 of 69 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
FGFR2 Fusion6
Derazantinib	Cholangiocarcinoma	Predictive	D	Supports Sensitivity Response	4	submitted	EID7969 ARQ 087 exhibited inhibitory effects biochemically, in cell line and cell cycle study of FGFR2 functions.

Cohorts

Alteration frequency by cohort (114)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

gdcObserved114 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Glioblastoma Multiforme TCGA-GBM	GlioblastomaCURATED_BROADER

Literature

Linked publications (12)

25 per page, newest first.

pubmedPublishedShowing 1–12 of 12 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
· Lancet Oncol · 2020 · PMID 32203698 · validated civic_curation pubmed
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.
· Lancet Gastroenterol Hepatol · 2021 · PMID 34358484 · validated civic_curation pubmed
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.
· J Clin Oncol · 2018 · PMID 29182496 · validated civic_curation pubmed
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.

FGFR2 W290C2
(oncogenic)	Lung Squamous Cell Carcinoma	Oncogenic	D	Supports Oncogenicity	3	accepted	EID7937 NIH-3T3 cells with the FGFR2 W290C extracellular domain mutation demonstrated an increase in colony formation in an anchorage independent growth assay, which was lost with the introduction of AP24534,… (full text at CIViC) PMID 23786770 · Liao et al., 2013 · Open in CIViC	civic
Futibatinib	Cholangiocarcinoma	Predictive	C	Supports Sensitivity Response	1	submitted	EID11633 In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC) PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC	civic

FGFR2 Y375C2
(functional)	—UNRESOLVED	Functional	D	Supports Gain Of Function	3	submitted	EID9355 FGFR2 Y375C was expressed in rat chondrosarcoma chondrocytes and was shown to increase activation of ERK and LRP6 relative to wild-type, as measured by western blot. FGFR2 Y375C also caused increased … (full text at CIViC) PMID 22558232 · Krejci et al., 2012 · Open in CIViC	civic
Futibatinib	Malignant Neoplasm of Unknown PrimaryALIAS	Predictive	C	Supports Sensitivity Response	2	submitted	EID11640 In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC) PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC	civic

FGFR2 Fusion + FGFR2 Fusion8
Derazantinib	Intrahepatic Cholangiocarcinoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID7329 Actionable fibroblast growth factor receptor 2 (FGFR2) fusions have been identified in intrahepatic cholangiocarcinomas (iCCA). Derazantinib, a multi-kinase inhibitor with potent pan-FGFR activity sho… (full text at CIViC) PMID 30420614 · Mazzaferro et al., 2019 · Open in CIViC	civic
Futibatinib	Intrahepatic Cholangiocarcinoma	Predictive	A	Supports Sensitivity Response	4	submitted	EID11609 In the phase 2 trial (NCT02052778), 103 patients (22-79 years of age) with unresectable or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements were treated with the … (full text at CIViC) PMID 36652354 · Goyal et al., 2023 · Open in CIViC	civic
〃	Intrahepatic Cholangiocarcinoma	Predictive	B	Supports Sensitivity Response	3	submitted	EID11612 In a phase 2 trial (NCT02052778) of the FGFR1/2/3/4 inhibitor futibatinib in 103 patients with previously treated intrahepatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements, the overal… (full text at CIViC) PMID 36652354 · Goyal et al., 2023 · Open in CIViC	civic
〃	Cholangiocarcinoma	Predictive	C	Supports Sensitivity Response	3	submitted	EID11632 In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC) PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC	civic
Infigratinib	Cholangiocarcinoma	Predictive	A	Supports Sensitivity Response	4	accepted	EID11230 This open-label phase 2 trial included 122 patients with histologically or cytologically confirmed, locally advanced or metastatic cholangiocarcinoma, 108 of whom had an FGFR2 fusion or rearrangement.… (full text at CIViC) PMID 34358484 · Javle et al., 2021 · Open in CIViC	civic
〃	Cholangiocarcinoma	Predictive	B	Supports Sensitivity Response	4	accepted	EID5908 This Phase II trial of BGJ398 for FGFR2 aberant cholangiocarcinoma included 48 patients with FGFR2 fusions. Among these patients with FGFR2 fusions, eight showed tumor response (18.8%) and thirty-six … (full text at CIViC) PMID 29182496 · Javle et al., 2018 · Open in CIViC	civic
〃	Cholangiocarcinoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID1913 Phase 1 study of FGFR-inhibitor BGJ398 (infigratinib) in advanced cancer with FGFR-aberrations (n=132). Two cholangiocarcinoma patients harbored FGFR2 fusions. Both were treated at BGJ398 doses >100mg… (full text at CIViC) PMID 27870574 · Nogova et al., 2017 · Open in CIViC	civic
Pemigatinib	Cholangiolocellular Small Duct Intrahepatic CholangiocarcinomaALIAS	Predictive	A	Supports Sensitivity Response	4	accepted	EID8173 In a multicentre, open-label, single-arm, phase 2 study (FIGHT-202), patients with disease progression following at least one previous treatment received a starting dose of 13·5 mg oral pemigatinib on… (full text at CIViC) PMID 32203698 · Abou-Alfa et al., 2020 · Open in CIViC	civic